Identifying the optimal timing of HER2 testing in patients with breast cancer: A Canadian economic evaluation

Current Oncology

Volumn 10, Issue 1, 2003, Pages 36-44

  Dranitsaris, George ^a   Norris, B ^b   Hanna, W ^c   O'Malley, F ^d   Gelmon, K ^b  

^a British Columbia Cancer Agency ^*  (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ALGORITHM; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COMPUTER MODEL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION SUPPORT SYSTEM; DRUG COST; DRUG INDICATION; HEALTH CARE POLICY; HUMAN; ONCOGENE NEU; PATIENT MONITORING; PROTEIN DETERMINATION; SCREENING; SIDE EFFECT;

EID: 0038625021     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Forbes JF. The control of breast cancer: the role of tamoxifen. Semin Oncol 1997;24(suppl 1):S1-5-S1-19.
2. Cooke T, Reeves J, Lannigan A, Stanton P. The value of human epidermal growth factor receptor-2 as a prognostic marker. Eur J Cancer 2001;37(suppl 1):S3-10.
3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of HER2/neu oncogene. Science 1987;235:177-82.
4. Paik S, Bryant J, Park C, et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361-70.
5. Andrulis IL, Bull SB, Blackstein ME, et al. neu/ErbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 1998;16:1340-9.
6. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2 overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
7. Norton I, Slamon D, Leyland-Jones B, et al. Overall survival advantage to simultaneous chemotherapy plus humanized anti-HER2 monoclonal antibody Herceptin in HER2 overexpressing metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 1999;18:127a.
8. Slamon D, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
9. Hanna W, Gelmon K. Update Of HER2/neu; predictive and prognostic value and testing recommendations. Current Oncology 2002;9(suppl 1):1-17.
10. Ravdin PM. Should HER2 status be routinely measured for all breast cancer patients? Semin Oncol 1999;26(suppl 12):117-23.
11. Ravdin P. The use of HER2 testing in the management of breast cancer. Semin Oncol 2000;27(suppl 9):33-42.
12. Pritchard KI, O'Malley FP, Andrulis I, et al. Prognostic and predictive value of HER2/neu in a randomized trial comparing CMF to CEF in premenopausal women with auxiliary lymph node positive breast cancer [abstract]. Proc Am Soc Clin Oncol 2002;20:165a.
13. Di Leo A, Chan S, Friedrichs K, et al. Biological markers (BM) with predictive value in metastatic breast cancer (MBC) patients (pts) randomly treated with doxorubicin (A) or docetaxel (D) [abstract]. Proc Am Soc Clin Oncol 2002;20:213a.
14. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with nodepositive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998;16:2651-8.
15. Statistics Canada, Health and Welfare Canada, and National Cancer Institute of Canada. Canadian Cancer Statistics 2001. Toronto: National Cancer Institute of Canada; 2001.
16. Will BP, Berthelot JM, Le Petit C, et al. Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer 2000;36:724-35.
17. Ridolfi RL, Jamehdor MR, Arber JM. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 2000;13:866-73.
18. Wolfson MC. POHEM - a framework for understanding and modeling the health of human populations. World Health Stat Q 1994;47:157-76.
19. Will BP, Berthelot JM, Nobrega KM, et al. Canada's Population Health Model (POHEM): a tool for performing economic evaluations of cancer control interventions. Eur J Cancer 2001;37:1797-804.
20. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000;92:1991-8.
21. Thor AD, Berry DA, Budman DR, et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346-60.
22. Nelson NJ. Experts debate value of HER2 testing methods. J Natl Cancer Inst 2000;16:292-4.
23. Piccart M, Lohrisch C, Di Leo A, Larsimont D. The predictive value of HER2 in breast cancer. Oncology 2001;61(suppl 2):73-82.
24. Piccart-Gebhart MJ. Herceptin: the future in adjuvant breast cancer therapy. Anticancer Drugs 2001;12(suppl 4):S27-33.
25. Hortobagyi GN, Perez EA. Integration of trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials. Semin Oncol 2001;28(suppl 16):41-6.